AARD vs RYTM vs VNDA vs IQV vs CRL vs JPM

For growth investors, Rhythm Pharmaceuticals, Inc.

(RYTM) is the stronger pick with 45. 8% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Aardvark Therapeutics, Inc. Common Stock (AARD) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus IQVIA Holdings Inc. at 23. 1x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 35x versus JPMorgan Chase & Co. 's 0. 81x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Rhythm Pharmaceuticals, Inc.

(RYTM) delivered a total return of +325. 3%, compared to -72. 7% for Aardvark Therapeutics, Inc. Common Stock (AARD). Over 10 years, the gap is even starker: JPM returned +465. 8% versus AARD's -72. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), JPMorgan Chase & Co.

(JPM) is the lower-risk stock at 0. 94β versus Aardvark Therapeutics, Inc. Common Stock's 2. 70β — meaning AARD is approximately 187% more volatile than JPM relative to the S&P 500. On balance sheet safety, Aardvark Therapeutics, Inc. Common Stock (AARD) carries a lower debt/equity ratio of 0% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Rhythm Pharmaceuticals, Inc.

(RYTM) is pulling ahead at 45. 8% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Rhythm Pharmaceuticals, Inc. grew EPS 28. 3% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, RYTM leads at 100. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -103. 6% for Rhythm Pharmaceuticals, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -101. 2% for RYTM. At the gross margin level — before operating expenses — VNDA leads at 94. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 35x versus JPMorgan Chase & Co. 's 0. 81x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, IQVIA Holdings Inc. (IQV) trades at 14. 2x forward P/E versus 16. 9x for Charles River Laboratories International, Inc. — 2. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AARD: 652. 1% to $29. 33.

In this comparison, JPM (1.

9% yield) pays a dividend. AARD, RYTM, VNDA, IQV, CRL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Aardvark Therapeutics, Inc. Common Stock (AARD) carries a higher beta of 2. 70 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, AARD: -72. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AARD (Healthcare) and RYTM (Healthcare) and VNDA (Healthcare) and IQV (Healthcare) and CRL (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AARD is a small-cap quality compounder stock; RYTM is a small-cap high-growth stock; VNDA is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock; CRL is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while AARD, RYTM, VNDA, IQV, CRL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.